Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells

Molecular Genetics and Metabolism

Volumn 100, Issue 4, 2010, Pages 372-378

  Zancan, Patricia ^a   Sola Penna, Mauro ^a   Furtado, Cristiane Marques ^a   Da Silva, Daniel ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Breast cancer; Enzyme; Glycolysis; Metabolism; Warburg

Indexed keywords

1 PHOSPHOFRUCTOKINASE; PYRUVATE KINASE; 6 PHOSPHOFRUCTOKINASE; ISOENZYME; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 10A; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METABOLOME; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; ISOENZYMES; METABOLOME; PHOSPHOFRUCTOKINASE-1; RNA, MESSENGER;

EID: 77954661063     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.04.006     Document Type: Article

References (46)

1. Robey I.F., Stephen R.M., Brown K.S., Baggett B.K., Gatenby R.A., Gillies R.J. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008, 10:745-756.
2. Altenberg B., Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84:1014-1020.
3. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res. 1978, 22:190-274.
4. Zu X.L., Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 2004, 313:459-465.
5. Rodrìguez-Enrìquez S., Marìn-Hern·ndez A., Gallardo-Pèrez J.C., Carreòo-Fuentes L., Moreno-S·nchez R. Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 2009, 53:29-48.
6. Walenta S., Schroeder T., Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr. Med. Chem. 2004, 11:2195-2204.
7. Walenta S., Mueller-Klieser W.F. Lactate: mirror and motor of tumor malignancy. Semin. Radiat. Oncol. 2004, 14:267-274.
8. Walenta S., Wetterling M., Lehrke M., Schwickert G., Sundfor K., Rofstad E.K., Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000, 60:916-921.
9. Sola-Penna M. Metabolic regulation by lactate. IUBMB Life 2008, 60:605-608.
10. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
11. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., De Young L.R., Lampidis T.J. 2-Deoxy-d-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004, 64:31-34.
12. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., Keating M.J., Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005, 65:613-621.
13. Lee K.A., Roth R.A., LaPres J.J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther. 2007, 113:229-246.
14. Spitz G.A., Furtado C.M., Sola-Penna M., Zancan P. Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem. Pharmacol. 2009, 77:46-53.
15. Schwartz M.K., Bodansky O. Utilization of automation for studies of enzyme kinetics. Methods Biochem. Anal. 1968, 16:183-218.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
17. Coelho W.S., Costa K.C., Sola-Penna M. Serotonin stimulates mouse skeletal muscle 6-phosphofructo-1-kinase through tyrosine-phosphorylation of the enzyme altering its intracellular localization. Mol. Genet. Metab. 2007, 92:364-370.
18. Khundmiri S.J., Asghar M., Khan F., Salim S., Yusufi A.N. Effect of ischemia and reperfusion on enzymes of carbohydrate metabolism in rat kidney. J. Nephrol. 2004, 17:377-383.
19. Iori E., Millioni R., Puricelli L., Arrigoni G., Lenzini L., Trevisan R., James P., Rossi G.P., Pinna L.A., Tessari P. Glycolytic enzyme expression and pyruvate kinase activity in cultured fibroblasts from type 1 diabetic patients with and without nephropathy. Biochim. Biophys. Acta 2008, 1782:627-633.
20. Diaz-Ruiz R., Uribe-Carvajal S., Devin A., Rigoulet M. Tumor cell energy metabolism and its common features with yeast metabolism. Biochim. Biophys. Acta (BBA) - Reviews on Cancer 2009, 1796:252-265.
21. Ashrafian H. Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. Lancet 2006, 367:618-621.
22. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104:19345-19350.
23. Kim J.W., Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006, 66:8927-8930.
24. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
25. Chen E.I., Hewel J., Krueger J.S., Tiraby C., Weber M.R., Kralli A., Becker K., Yates J.R., Felding-Habermann B. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007, 67:1472-1486.
26. Burghaus S., Holsken A., Buchfelder M., Fahlbusch R., Riederer B.M., Hans V., Blumcke I., Buslei R. A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch. 2010, 456:287-300.
27. Greenfield J.P., Cobb W.S., Lyden D. Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J. Clin. Invest. 2010, 120:663-667.
28. Hendriksen P.J., Dits N.F., Kokame K., Veldhoven A., van Weerden W.M., Bangma C.H., Trapman J., Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006, 66:5012-5020.
29. Acs G., Xu X., Chu C., Acs P., Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004, 100:2376-2386.
30. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981.
31. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
32. El-Bacha T., de Freitas M.S., Sola-Penna M. Cellular distribution of phosphofructokinase activity and implications to metabolic regulation in human breast cancer. Mol. Genet. Metab. 2003, 79:294-299.
33. Leite T.C., Da Silva D., Coelho R.G., Zancan P., Sola-Penna M. Lactate favours the dissociation of skeletal muscle 6-phosphofructo-1-kinase tetramers down-regulating the enzyme and muscle glycolysis. Biochem. J. 2007, 408:123-130.
34. Marinho-Carvalho M.M., Costa-Mattos P.V., Spitz G.A., Zancan P., Sola-Penna M. Calmodulin upregulates skeletal muscle 6-phosphofructo-1-kinase reversing the inhibitory effects of allosteric modulators. Biochim. Biophys. Acta (BBA) - Proteins & Proteomics 2009, 1794:1175-1180.
35. Zancan P., Sola-Penna M. Calcium influx: a possible role for insulin modulation of intracellular distribution and activity of 6-phosphofructo-1-kinase in human erythrocytes. Mol. Genet. Metab. 2005, 86:392-400.
36. Zancan P., Sola-Penna M. Regulation of human erythrocyte metabolism by insulin: cellular distribution of 6-phosphofructo-1-kinase and its implication for red blood cell function. Mol. Genet. Metab. 2005, 86:401-411.
37. Meira D.D., Marinho-Carvalho M.M., Teixeira C.A., Veiga V.F., Da Poian A.T., Holandino C., de Freitas M.S., Sola-Penna M. Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes. Mol. Genet. Metab. 2005, 84:354-362.
38. Zancan P., Rosas A.O., Marcondes M.C., Marinho-Carvalho M.M., Sola-Penna M. Clotrimazole inhibits and modulates heterologous association of the key glycolytic enzyme 6-phosphofructo-1-kinase. Biochem. Pharmacol. 2007, 73:1520-1527.
39. Glass-Marmor L., Beitner R. Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Eur. J. Pharmacol. 1999, 370:195-199.
40. Schwartz D., Beitner R. Detachment of the glycolytic enzymes, phosphofructokinase and aldolase, from cytoskeleton of melanoma cells, induced by local anesthetics. Mol. Genet. Metab. 2000, 69:159-164.
41. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
42. Kim J.W., Dang C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30:142-150.
43. Deng H., Yu F., Chen J., Zhao Y., Xiang J., Lin A. Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J. Biol. Chem. 2008, 283:20754-20760.
44. Lilling G., Beitner R. Decrease in cytoskeleton-bound phosphofructokinase in muscle induced by high intracellular calcium, serotonin and phospholipase A2 in vivo. Int. J. Biochem. 1990, 22:857-863.
45. Lilling G., Beitner R. Altered allosteric properties of cytoskeleton-bound phosphofructokinase in muscle from mice with X chromosome-linked muscular dystrophy (mdx). Biochem. Med. Metab. Biol. 1991, 45:319-325.
46. Marin-Hernandez A., Gallardo-Perez J.C., Ralph S.J., Rodriguez-Enriquez S., Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem. 2009, 9:1084-1101.